1. Home
  2. DQ vs MESO Comparison

DQ vs MESO Comparison

Compare DQ & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DAQO New Energy Corp.

DQ

DAQO New Energy Corp.

HOLD

Current Price

$32.00

Market Cap

2.2B

Sector

Technology

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$17.79

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DQ
MESO
Founded
2006
2004
Country
China
Australia
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
1.8B
IPO Year
2010
N/A

Fundamental Metrics

Financial Performance
Metric
DQ
MESO
Price
$32.00
$17.79
Analyst Decision
Buy
Strong Buy
Analyst Count
4
2
Target Price
$32.50
$24.00
AVG Volume (30 Days)
911.9K
211.8K
Earning Date
10-27-2025
08-28-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$639,063,000.00
$17,198,000.00
Revenue This Year
N/A
$465.44
Revenue Next Year
$58.56
$75.37
P/E Ratio
N/A
N/A
Revenue Growth
N/A
191.39
52 Week Low
$12.41
$9.61
52 Week High
$36.59
$22.00

Technical Indicators

Market Signals
Indicator
DQ
MESO
Relative Strength Index (RSI) 50.75 56.73
Support Level $31.72 $16.43
Resistance Level $34.50 $17.65
Average True Range (ATR) 1.60 0.59
MACD -0.04 0.16
Stochastic Oscillator 47.40 56.31

Price Performance

Historical Comparison
DQ
MESO

About DQ DAQO New Energy Corp.

Daqo New Energy Corp is a polysilicon manufacturer based in China. The company manufactures and sells high-purity polysilicon to manufacturers who use it to make ingots, cells, and modules for solar power solutions. The polysilicon is packaged to meet crucible stacking, pulling, and solidification needs. All of the company's revenues come from the People's Republic of China.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: